Skip to main content
SpringerLink
Log in

Effects of Addition of Policosanol to Omega-3 Fatty Acid Therapy on the Lipid Profile of Patients with Type II Hypercholesterolaemia

  • Original Research Article
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Background: Policosanol is a mixture of higher aliphatic primary alcohols purified from sugar-cane wax. The mixture has cholesterol-lowering efficacy, its specific effects being to reduce serum total (TC) and low-density lipoprotein cholesterol (LDL-C), and to increase high-density lipoprotein cholesterol (HDL-C). The effects of policosanol on triglycerides (TG) are modest and inconsistent. Omega-3 fatty acids (FA) from fish oil protect against coronary disease, mainly through antiarrhythmic and antiplatelet effects. Omega-3 FA also have lipid-modifying effects, mostly relating to TG reduction. Thus, potential benefits could be expected from combined therapy with omega-3 FA and policosanol.

Objective: To investigate whether combined therapy with omega-3 FA + policosanol offers benefits compared with omega-3 FA + placebo with respect to the lipid profile of patients with type II hypercholesterolaemia.

Methods: This randomised, double-blind study was conducted in 90 patients with type II hypercholesterolaemia. After 5 weeks on a cholesterol-lowering diet, patients were randomised to omega-3 FA + placebo, omega-3 FA + policosanol 5 mg/day or omega-3 FA + policosanol 10 mg/day for 8 weeks. Omega-3 FA was supplied as 1g capsules (two per day); placebo and policosanol were provided in tablet form. Physical signs and laboratory markers were assessed at baseline and after 4 and 8 weeks on therapy. Drug compliance and adverse experiences (AEs) were assessed at weeks 4 and 8. The primary efficacy variable was LDL-C reduction; other lipid profile markers were secondary variables.

Results: After 8 weeks, omega-3 FA + policosanol 5 and 10 mg/day, but not omega-3 FA + placebo, significantly reduced LDL-C by 21.1% and 24.4%, respectively (both p < 0.0001). Omega-3 FA + policosanol 5 mg/day also significantly lowered TC (12.7%; p < 0.01) and TG (13.6%; p < 0.05), and significantly increased HDL-C (+14.4%; p < 0.001). Omega-3 FA + policosanol 10 mg/day significantly decreased TC (15.3%; p < 0.001) and TG (14.7%; p < 0.01), and significantly increased HDL-C (+15.5%; p < 0.0001). Omega-3 FA + placebo significantly reduced TG (14.2%; p < 0.05) but had no significant effect on other lipid profile variables. The proportion of randomised patients in the omega-3 FA + policosanol 5 or 10 mg/day groups that achieved LDL-C targets or reductions ≥15% was significantly greater than in the omega-3 FA + placebo group (p < 0.001). Combined therapy with omega-3 FA + policosanol 5 or 10 mg/day resulted in significantly greater changes in LDL-C, TC and HDL-C than treatment with omega-3 FA + placebo, but did not modify the TG response compared with the omega-3 FA + placebo group.

Four patients (two in the omega-3 FA + placebo group and two in the omega-3 FA + policosanol 10 mg/day group) withdrew from the study; none of these withdrawals was due to AEs. Two patients reported mild AEs, namely nausea/headache (one in the omega-3 FA + placebo group) and heartburn (one in the omega-3 FA + policosanol 5 mg/day group).

Conclusions: Policosanol 5 or 10 mg/day administered concomitantly with omega-3 FA 1 g/day improved LDL-C, TC and HDL-C, maintained the reduction in TG attributable to omega-3 FA monotherapy, and was well tolerated. Treatment with omega-3 FA + policosanol could be useful for regulating lipid profile in patients with type II hypercholesterolaemia, but further studies involving larger sample sizes are needed before definitive conclusions can be drawn.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351–64

    Article  Google Scholar 

  2. Lipid Research Clinic Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA 1984; 251: 365–74

    Article  Google Scholar 

  3. Frick MH, Elo O, Happa K. Helsinki Heart Study: primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237–45

    Article  PubMed  CAS  Google Scholar 

  4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S): Lancet 1994; 344: 1383–9

    Google Scholar 

  5. Sacks FM, Pfeffer MA, Moyé LA, et al. for the Cholesterol and Recurrent Events Trial Investigators: the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9

    Article  PubMed  CAS  Google Scholar 

  6. The Long-Term Intervention with pravastatin in ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57

    Article  Google Scholar 

  7. Shepherd S, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7

    Article  PubMed  CAS  Google Scholar 

  8. Downs JR, Clearfield M, Weiss S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22

    Article  PubMed  CAS  Google Scholar 

  9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7–22

    Article  Google Scholar 

  10. Shepherd J, Blauw GJ, Murphy MB, et al. on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled study. Lancet 2002; 360: 1623–30

    Article  PubMed  CAS  Google Scholar 

  11. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97

    Article  Google Scholar 

  12. Gotto AM, Assman G, Carmena R, et al. The ILIB lipid handbook for clinical practice. Blood lipids and coronary heart disease. 2nd ed. New York: International Lipid Information Bureau (ILIB), 2000

    Google Scholar 

  13. Mas R. Policosanol. Drugs of the Future 2000; 25: 569–86

    Article  CAS  Google Scholar 

  14. Ortensi G, Gladstein H, Valli H, et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997; 58: 390–401

    Article  CAS  Google Scholar 

  15. Mas R, Castaño G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1998; 65: 439–47

    Article  Google Scholar 

  16. Castaño G, Más R, Arruzazabala ML, et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999; 19: 105–16

    PubMed  Google Scholar 

  17. Castaño G, Más R, Fernández L, et al. Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000; 13: 187–95

    Article  Google Scholar 

  18. Mas R, Castaño G, Fernández L, et al. Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin Drug Invest 2001; 21: 485–97

    Article  CAS  Google Scholar 

  19. Castaño G, Mas R, Fernández L, et al. Comparison of the efficacy, safety and tolerability of policosanol versus atorvastatin in elderly patients with type II hypercholesterolemia. Drugs Aging 2003; 20: 153–63

    Article  PubMed  Google Scholar 

  20. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995; 18: 393–7

    Article  PubMed  CAS  Google Scholar 

  21. Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999; 19: 105–16

    Google Scholar 

  22. Castaño G, Fernández L, Mas R, et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidemia and type 2 diabetes mellitus. Clin Drug Invest 2003; 23: 639–50

    Article  Google Scholar 

  23. Menéndez R, Fernández I, Del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res 1994; 27: 199–203

    Article  PubMed  Google Scholar 

  24. Menéndez R, Arruzazabala ML, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr 1996; 77: 923–32

    Article  Google Scholar 

  25. Menéndez R, Amor A, Rodeiro I, et al. Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res 2001; 32: 8–12

    Article  PubMed  Google Scholar 

  26. Arruzazabala ML, Valdés S, Más R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 1996; 34: 181–5

    Article  PubMed  CAS  Google Scholar 

  27. Arruzazabala ML, Más R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 1998; 20: 119–24

    PubMed  CAS  Google Scholar 

  28. Menéndez R, Más R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000; 50: 255–62

    Article  PubMed  Google Scholar 

  29. Menéndez R, Más R, Amor A, et al. Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: a randomised, double-blinded pilot study. Curr Ther Res 2000; 61: 609–20

    Article  Google Scholar 

  30. Gámez R, Alemán CL, Mas R, et al. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague Dawley rats. J Med Food 2001; 4: 57–66

    Article  PubMed  Google Scholar 

  31. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in beagle dogs: one year study. Toxicol Lett 1994; 73: 81–90

    Article  PubMed  CAS  Google Scholar 

  32. Rodríguez MD, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 1994; 14: 107–13

    Article  PubMed  Google Scholar 

  33. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: a 24 month study. Teratog Carcinog Mutagen 1994; 14: 239–49

    Article  PubMed  Google Scholar 

  34. Harris WS, Park Y, Isley WL. Cardiovascular disease and long chain omega-3 fatty acids. Curr Opin Lipidol 2003; 14: 9–14

    Article  PubMed  CAS  Google Scholar 

  35. Lee KW, Lip GV. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM 2003; 96: 465–80

    Article  PubMed  CAS  Google Scholar 

  36. Richtner WO. Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease. Eur J Med Res 2003; 8: 332–6

    Google Scholar 

  37. Lemaitre RN, King IB, Mozaffarian D, et al. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease and non fatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr 2003; 77: 319–25

    PubMed  CAS  Google Scholar 

  38. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815–21

    Article  PubMed  CAS  Google Scholar 

  39. De Caterina R, Madonna R, Zucchi R, et al. Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. Am Heart J 2003; 146: 420–30

    Article  PubMed  Google Scholar 

  40. Mori TA, Beilin LJ. Long-chain omega 3 fatty acids, blood lipids and cardiovascular reduction. Curr Opin Lipidol 2001; 12: 11–7

    Article  PubMed  CAS  Google Scholar 

  41. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197–204

    Article  PubMed  CAS  Google Scholar 

  42. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45

    Article  PubMed  CAS  Google Scholar 

  43. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 1981; 27: 838–41

    PubMed  CAS  Google Scholar 

  44. Friedewald WT, Levy IR, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502

    PubMed  CAS  Google Scholar 

  45. Suzukawa M, Abbey M, Howe PRC, et al. Effects of fish oil fatty acids on low-density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 1995; 36: 473–84

    PubMed  CAS  Google Scholar 

  46. Harris W. Fish oil and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989; 30: 785–807

    PubMed  CAS  Google Scholar 

  47. Nestel PJ. Effects of n-3 fatty acids on lipid metabolism. Annu Rev Nutr 1990; 10: 149–67

    Article  PubMed  CAS  Google Scholar 

  48. Sandset PM, Lund H, Norseth J, et al. Treatment with hydroxy-methylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in components of the extrinsic coagulation system. Arterioscler Thromb Vasc Biol 1991; 11: 138–45

    Article  CAS  Google Scholar 

  49. Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega 3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidaemia. Arterioscler Thromb 1993; 13: 1755–62

    Article  PubMed  CAS  Google Scholar 

  50. Nordoy A, Bonaa KH, Nilsen H, et al. Effects of simvastatin and omega 3 fatty acids on plasma lipoprotein and lipid peroxida- tion in patients with combined hyperlipidaemia. J Intern Med 1998; 243: 163–70

    Article  PubMed  CAS  Google Scholar 

  51. Durrington PN, Bhatnagar D, Mackness MI, et al. The effects of an omega-3 fatty polyunsaturated acid concentrate administered for one year to simvastatin treated patients with established coronary artery disease and persisting hypertriglyceridemia. Heart 2001; 85: 544–8

    Article  PubMed  CAS  Google Scholar 

  52. Chan DC, Watts GF, Barrett HR, et al. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002; 48: 877–83

    PubMed  CAS  Google Scholar 

  53. Bhatnagar D, Mackness MI, Durrington PN. Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMGCoA reductase inhibitors. Eur Heart J Suppl 2001; 3 Suppl. D: D53–8

    CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by a research grant from the West Havana Scientific Pole. The people involved in this study did not receive any financial or other compensation for their participation in the study.

The authors have no potential conflicts of interest that are directly relevant to the contents of this article.

Author information

Authors and Affiliations

  1. Surgical Medical Research Center, Center of Natural Products from the National Center of Scientific Research (CNIC), 6990 or 6880, Playa, PO Box, Havana City, Cuba

    G. Castaño, L. Fernández,  R. Mas, J. Illnait, R. Gámez, S. Mendoza, M. Mesa & J. Fernández

Authors
  1. G. Castaño
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Mas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Illnait
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Gámez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Mesa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Mas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castaño, G., Fernández, L., Mas, R. et al. Effects of Addition of Policosanol to Omega-3 Fatty Acid Therapy on the Lipid Profile of Patients with Type II Hypercholesterolaemia. Drugs R D 6, 207–219 (2005). https://doi.org/10.2165/00126839-200506040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200506040-00003

Keywords

Search

Navigation